Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...
Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback